Testing a new antibody treatment for advanced prostate cancer

Plain-English translation of NCT06842498 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a Phase 2 clinical trial testing a new medication called for men with metastatic castration-resistant prostate cancer — a type of advanced prostate cancer that no longer responds to standard hormone treatments. The study will test three different doses of the medication to find the right balance between effectiveness and safety. About 75 men will participate to help determine whether this treatment works and how well patients tolerate it.

Men whose prostate cancer stops responding to current hormone therapies have limited options and need new treatments. This medication works in a different way than existing drugs, targeting a protein called CD46 that appears on cancer cells, offering hope for patients who have run out of other choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced prostate cancer that has spread to other parts of your body and stopped responding to hormone treatment
you have tried only one type of second-generation hormone therapy (such as abiraterone, enzalutamide, apalutamide, or darolutamide) before entering the study
you have not received chemotherapy for your metastatic prostate cancer, though you may have received it earlier for hormone-sensitive disease
you have confirmed prostate cancer on biopsy and at least one area of cancer visible on imaging scans within 28 days of starting
your testosterone levels are below 50 ng/dL during screening
you have adequate kidney, heart, and liver function

You likely don't qualify if…

you have received previous treatment with any drug targeting CD46
you have a type of prostate cancer with small cell or neuroendocrine features
you have tried more than one second-generation hormone therapy or received more than two of these drugs total
you have grade 2 or worse nerve damage from any cause
you have another cancer diagnosed in the past 5 years (except non-melanoma skin cancer)

What participation looks like

You will receive an intravenous infusion of the medication once every 3 weeks on an outpatient basis. The study will assign you to one of three dose groups to test which dose works best. You will continue receiving the treatment until your cancer progresses, you experience unacceptable side effects, or your doctor decides it's no longer appropriate — which may be weeks or months depending on how you respond.

AI-generated summary from trial data · Aug 20, 2026 · Not medical advice

Trial locations(23 sites)

United States

Western Regional Medical Center - City of Hope Phoenix Goodyear, Goodyear, Arizona

HonorHealth Research Institute, Scottsdale, Arizona

The University of Arizona Cancer Center - North Campus, Tucson, Arizona

VA Greater Los Angeles Healthcare System, Los Angeles, California

UCLA Clark Urology Center, Los Angeles, California